{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:19:06Z","timestamp":1747196346427,"version":"3.40.5"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Patients with plasma cell disorders (PCD) are at an increased risk for severe morbidity and mortality due to COVID-19. Recent data have suggested that patients with hematological malignancies, including those with PCD, have suboptimal antibody response to COVID-19 vaccination. We compared the antibody titers of 213 patients with PCD to those of 213 immunocompetent healthcare workers after the second vaccine dose of the BNT162b2 mRNA vaccine. Blood samples were taken 2\u20134 weeks after the second vaccination and analyzed for anti-receptor binding-domain immunoglobulin G (RBD-IgG) antibodies and neutralizing antibodies (NA). At a median of 20 days after the second vaccine dose, 172 patients (80.8%) developed anti-RBD-IgG antibodies with a geometric mean titer (GMT) of 2.7 (95% confidence interval [CI], 2.4\u20133.1). In the control group 210 (98.9%) developed anti-RBD-IgG antibodies after a median of 21 days, with a GMT of 5.17 (95%CI, 4.8\u20135.6), p&lt;0.0001. NA were observed in 151 patients with MM (70.9%) and in 210 controls (98.9%). The GMT of NA in patients with MM and controls was 84.4 (95% CI, 59.0\u2013120.6), and 420.2 (95% CI, 341.4\u2013517.1), respectively (p&lt;0.0001). Multivariable logistic regression revealed that the number of prior therapy lines and age were significant predictors of poor humoral response among patients with MM. Injection site reaction, headache and fatigue were the most common adverse events after vaccination. Adverse events were less common in patients with MM than in controls. In conclusion, a significant percentage of patients with MM developed protecting NA to the BNT162b2 mRNA vaccine, which appears to be safe in this patient population.<\/jats:p>","DOI":"10.1371\/journal.pone.0284925","type":"journal-article","created":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T17:24:15Z","timestamp":1682961855000},"page":"e0284925","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-RBD IgG antibodies and neutralizing antibody levels after the second BNT162b2 dose in patients with plasma cell disorders"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3990-394X","authenticated-orcid":true,"given":"Hila","family":"Magen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Avigdor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee","family":"Nevo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalev","family":"Fried","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Gibori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4915-8493","authenticated-orcid":true,"given":"Einav G.","family":"Levin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaniv","family":"Lustig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eden","family":"Shkury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galia","family":"Rahav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,5,1]]},"reference":[{"key":"pone.0284925.ref001","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13584-021-00440-6","article-title":"Israel\u2019s rapid rollout of vaccinations for COVID-19","volume":"10","author":"B Rosen","year":"2021","journal-title":"Israel Journal of Health Policy Research"},{"key":"pone.0284925.ref002","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/14656566.2020.1849143","article-title":"The management of hematologic malignancies during the COVID-19 pandemic.","volume":"22","author":"I Hus","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"pone.0284925.ref003","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S1470-2045(20)30442-3","article-title":"COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study","volume":"21","author":"LYW Lee","year":"2020","journal-title":"Lancet Oncol"},{"key":"pone.0284925.ref004","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/bjh.17441","article-title":"Development of antibody response to SARS-CoV-2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy","volume":"194","author":"WY Chan","year":"2021","journal-title":"Br J Haematol"},{"key":"pone.0284925.ref005","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1158\/2159-8290.CD-20-0422","article-title":"Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak.","volume":"10","author":"M Dai","year":"2020","journal-title":"Cancer Discov."},{"key":"pone.0284925.ref006","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1097\/HS9.0000000000000547","article-title":"SARS-CoV-2 Vaccines in Patients With Multiple Myeloma.","volume":"5","author":"M Gavriatopoulou","year":"2021","journal-title":"Hemasphere"},{"key":"pone.0284925.ref007","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1182\/blood.2020008150","article-title":"Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set","volume":"136","author":"A Chari","year":"2020","journal-title":"Blood"},{"key":"pone.0284925.ref008","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults","volume":"383","author":"EJ Anderson","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0284925.ref009","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"FP Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0284925.ref010","article-title":"Safety and efficacy of BNT162b mRNA Covid19 Vaccine in patients with chronic lymphocytic leukemia","author":"O Benjamini","year":"2021","journal-title":"Haematologica"},{"key":"pone.0284925.ref011","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"S Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"pone.0284925.ref012","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.chom.2020.06.020","article-title":"A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition.","volume":"28","author":"ME Dieterle","year":"2020","journal-title":"Cell Host Microbe"},{"key":"pone.0284925.ref013","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/blood.2021011904","article-title":"Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose","volume":"137","author":"E Terpos","year":"2021","journal-title":"Blood"},{"key":"pone.0284925.ref014","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41408-021-00528-x","article-title":"Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia","volume":"11","author":"H Parry","year":"2021","journal-title":"Blood Cancer J"},{"key":"pone.0284925.ref015","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S2352-3026(21)00199-X","article-title":"Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma","volume":"8","author":"SH Lim","year":"2021","journal-title":"Lancet Haematol"},{"key":"pone.0284925.ref016","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.ccell.2021.07.016","article-title":"Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer","volume":"39","author":"S Ehmsen","year":"2021","journal-title":"Cancer Cell"},{"key":"pone.0284925.ref017","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ccell.2021.07.012","article-title":"Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies","volume":"39","author":"LM Greenberger","year":"2021","journal-title":"Cancer Cell"},{"key":"pone.0284925.ref018","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1182\/bloodadvances.2021005444","article-title":"Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study","volume":"5","author":"M Gavriatopoulou","year":"2021","journal-title":"Blood Adv"},{"key":"pone.0284925.ref019","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ccell.2021.06.014","article-title":"Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma","volume":"39","author":"O Van Oekelen","year":"2021","journal-title":"Cancer Cell"},{"key":"pone.0284925.ref020","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1016\/S2352-3026(21)00169-1","article-title":"Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study","volume":"8","author":"K Maneikis","year":"2021","journal-title":"Lancet Haematol"},{"key":"pone.0284925.ref021","article-title":"Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients.","author":"M Agha","year":"2021","journal-title":"medRxiv"},{"key":"pone.0284925.ref022","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.healun.2021.04.003","article-title":"BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response","volume":"40","author":"Y Peled","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"pone.0284925.ref023","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1097\/TP.0000000000003889","article-title":"Humoral Response of Renal Transplant Recipients to the BNT162b2 SARS-CoV-2 mRNA Vaccine Using Both RBD IgG and Neutralizing Antibodies","volume":"105","author":"T Hod","year":"2021","journal-title":"Transplantation"},{"key":"pone.0284925.ref024","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S2213-2600(21)00220-4","article-title":"BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers","volume":"9","author":"Y Lustig","year":"2021","journal-title":"The Lancet Respiratory Medicine"},{"key":"pone.0284925.ref025","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"SA Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"pone.0284925.ref026","doi-asserted-by":"crossref","first-page":"814","DOI":"10.5858\/arpa.2022-0041-SA","article-title":"Anti-Receptor-Binding Domain Immunoglobulin G Antibody as a Predictor of Seropositivity for Anti-SARS-CoV-2 Neutralizing Antibody","volume":"146","author":"JH Xue","year":"2022","journal-title":"Arch Pathol Lab Med"},{"key":"pone.0284925.ref027","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"MJ Mulligan","year":"2020","journal-title":"Nature"},{"key":"pone.0284925.ref028","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/bjh.17608","article-title":"Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma","volume":"195","author":"I Avivi","year":"2021","journal-title":"Br J Haematol"},{"key":"pone.0284925.ref029","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41375-020-01016-0","article-title":"Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network","volume":"35","author":"H Ludwig","year":"2021","journal-title":"Leukemia"},{"key":"pone.0284925.ref030","doi-asserted-by":"crossref","first-page":"E443","DOI":"10.1002\/ajh.26348","article-title":"Antibody response to COVID-19 mRNA vaccine (Comirnaty) in myeloma patients treated with high-dose melphalan and\/or immunotherapy.","volume":"96","author":"S Lockmer","year":"2021","journal-title":"Am J Hematol"},{"key":"pone.0284925.ref031","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-021-01090-6","article-title":"Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution","volume":"14","author":"F Pimpinelli","year":"2021","journal-title":"J Hematol Oncol"},{"key":"pone.0284925.ref032","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1158\/2643-3230.BCD-21-0139","article-title":"Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies.","volume":"2","author":"DJ Chung","year":"2021","journal-title":"Blood Cancer Discovery"},{"key":"pone.0284925.ref033","doi-asserted-by":"crossref","first-page":"e0259822","DOI":"10.1371\/journal.pone.0259822","article-title":"Chronic diseases associated with increased likelihood of hospitalization and mortality in 68,913 COVID-19 confirmed cases in Spain: A population-based cohort study.","volume":"16","author":"A Gimeno-Miguel","year":"2021","journal-title":"PLoS One"},{"key":"pone.0284925.ref034","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10173855","article-title":"Specific Risk Factors for Fatal Outcome in Critically Ill COVID-19 Patients: Results from a European Multicenter Study.","volume":"10","author":"D Meintrup","year":"2021","journal-title":"J Clin Med."},{"key":"pone.0284925.ref035","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1126\/science.abd2321","article-title":"Structural basis of a shared antibody response to SARS-CoV-2","volume":"369","author":"M Yuan","year":"2020","journal-title":"Science"},{"key":"pone.0284925.ref036","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/ajh.26284","article-title":"BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies","volume":"96","author":"K Herzog Tzarfati","year":"2021","journal-title":"Am J Hematol"},{"key":"pone.0284925.ref037","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13045-021-01183-2","article-title":"Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls.","volume":"14","author":"S Bitoun","year":"2021","journal-title":"J Hematol Oncol."},{"key":"pone.0284925.ref038","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"LR Baden","year":"2021","journal-title":"N Engl J Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0284925","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T17:24:45Z","timestamp":1682961885000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0284925"}},"subtitle":[],"editor":[{"given":"Debdutta","family":"Bhattacharya","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0284925","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2023,5,1]]}}}